

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the

HIROFUMI YURA ET AL.

Application of:

Application No.:

09/937,991

Filing Date:

01/23/2002

Title:

FUNCTIONALIZED

GLYCOSAMINOGLYCAN POLYMER AND MEDICAL

INSTRUMENTS AND DRUGS BY

USING THE SAME

KRISHNAN,

Examiner:

GANAPATHY

Art Unit:

1623

AUG 2 0 2003 TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL

The Assistant Commissioner for Patents **BOX FEE AMENDMENT** P.O. Box 1450 Alexandria, VA 22313-1450

Transmitted herewith is an amendment for this application.

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as 1st Class Mail addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on <u>68/14/03</u>

The fee for claims has been calculated as shown below:

CLAIMS	FOR	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	CALCULATIONS
	TOTAL CLAIMS (37 C.F.R. § 1.16(c))		- 20	= 0	x \$18.00 =	\$
	INDEPENDENT CLAIMS (37 C.F.R. § 1.16(b))				40400	
	(37 C.F.R. § 1.16(b)) - 3 = x \$84.00 = MULTIPLE DEPENDENT CLAIMS (if applicable) (37 C.F.R. § 1.16(d)) + \$280.00					\$
	Reduction by	\$				
				=	TOTAL =	\$

	Applicant hereby claims small entity status under 37 C.F.R. § 1.27.						
	A check is enclosed to cover the \$\sum_{\text{fee}}\$ fee for the presentation of additional claims.						
XX	Applicant believes that no extension of time is required. However, this conditional petition is being made to provide for the possibility that Applicant has inadvertently overlooked the need for a petition for an extension of time.						
	Applicant hereby petitions for a:						
	one month (37 C.F.R. § 1.17(a): \$110.00/\$55.00)						
	two month (37 C.F.R. § 1.17(b): \$410.00/\$205.00)						
	three month (37 C.F.R. § 1.17(c): \$930.00/\$465.00)						
	four month (37 C.F.R. § 1.17(d): \$1,450.00/\$725.00)						
	five month (37 C.F.R. § 1.17(d): \$1,967.00/\$9850.00)						
	extension of time pursuant to 37 C.F.R. § 1.136(a). If an additional extension of time is required, please consider this a petition therefor.						
	A check is enclosed to cover the \$ extension of time fee under 37 C.F.R. § 1.17.						
	Charge Deposit Account No. 16-0820 (our Order No. S&P.33944) in the amount of \$						

X The Commissioner is hereby authorized to credit any overpayment or to charge any fees under 37 C.F.R. §§ 1.16, 1.17 in connection with this communication to our Deposit Account No. 16-0820 (our Order No.S&P.33944).

Date: Myst 14, 2003

Respectfully submitted,

Paul A. Serbinowski, Reg. No. 34429

PEARNE & GORDON LLP

Ohio Savings Building 526 Superior Avenue East Suite 1200

Cleveland, OH 44114

Phone: (216) 579-1700 Facsimile: (216) 579-6073



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hirofumi Yura et al.

AUG 2 0 2003

Serial No.: 09/937,991

Group Art Unit: 1623

TECH CENTER 1600/2900

Filed: 01/23/2002

Examiner: Krishnan, Ganapathy

Title:

FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND MEDICAL

INSTRUMENTS AND DRUGS BY USING THE SAME

Docket:

33944

Pearne & Gordon LLP 526 Superior Avenue East

Suite 1200

Cleveland, OH 44114-1484 Telephone: (216) 579-1700 Facsimile: (216)579-6073 Email:ip@pearnegordon.com

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENT

Dear Sir:

This is in response to the Office Action mailed July 15, 2003. Applicants hereby provisionally elect, with traverse, to prosecute the following:

a) The invention of Group I, drawn to a functionalized polymer having the structure:

-(CWX-CYZ)n- (claims 1-3 and 6-10 falling into elected Group I); and

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as first class mail addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: 08/14/03

By: Toller M Bezelak ...

b) The species for W in formula I: heparin/heparan sulfate or a partially desulfated modification thereof as listed in claim 3 (claims 3, 9 and 10 being readable on the elected species).

Currently, independent claims 1 and 7 are generic to all species. Claims 3, 5, 9 and 10 depend from claims 1 or 7. It is noted that when claims to nonelected species are fully embraced by allowable generic claims, the claims shall no longer be withdrawn. MPEP 809.02. Upon the allowance of claims 1 and 7 all claims which depend therefrom should be in condition for allowance including claims 3, 9 and 10 which feature the non-elected species and claim 5 which features the nonelected invention of Group II.

The Office Action asserts that the inventions of the two groups do not relate to the same inventive concept because they lack the same technical features under PCT rules. Applicants' undersigned representative respectfully notes that U.S. law and regulations control in this U.S. national patent application. Upon the allowance of claim 1, Applicants reserve the right to reintroduce the nonelected invention of claim 5. Also, upon the allowance of generic claims 1 or 7 Applicants also reserve the right to reintroduce the nonelected species featured in claims 3, 9 or 10.

The avowed purpose of the Patent and Trademark Office in requiring restriction, is the avoidance of a burdensome examination and multiple surfaces. However, MPEP §803 provides that if the search and examination of an entire application can be made without serious burden the Examiner must do so even if it is considered to include claims to two different or independent inventions.

It is respectfully submitted that the examination of all of the claims of this application will not place an undue burden on the PTO. Accordingly, Applicants

Serial No. 09/937,991 Docket No. 33944

respectfully request that the Examiner withdraw the restriction and species requirements and that he concurrently examine the claims of Groups I and II and all species in this application.

Respectfully submitted,

Pearne & Gordon LLP

Dated: August 14, 2003

y: If can

Paul A. Serbinowski

Reg. No. 34,429